China Oncology ›› 2017, Vol. 27 ›› Issue (6): 459-462.doi: 10.19401/j.cnki.1007-3639.2017.06.010
Previous Articles Next Articles
GUO Ye
Online:
Published:
Contact:
Abstract: The predominant type of head and neck cancer is head and neck squamous cell carcinoma (HNSCC), which needs more effective treatment. As a highly immunosuppressive malignancy, HNSCC has 3 major mechanisms including induction of immune tolerance, local immune evasion, and disruption of T-cell signaling. Immune checkpoint plays a critical role in the function of T-cell and rapid development has been achieved by inhibiting programmed cell death 1 (PD-1). As anti-PD1 humanized monoclonal antibodies, pembrolizumab and nivolumab have proven to be effective in the salvage treatment for recurrent or metastatic HNSCC, further investigation is awaited.
Key words: Head and neck squamous cell carcinoma, Immunotherapy, Immune checkpoint inhibitor
GUO Ye. The immunotherapy for head and neck cancer[J]. China Oncology, 2017, 27(6): 459-462.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://www.china-oncology.com/EN/10.19401/j.cnki.1007-3639.2017.06.010
http://www.china-oncology.com/EN/Y2017/V27/I6/459